Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| XOMA Corporation Snapshot | 5 | 2 |
| XOMA Corporation Overview | 5 | 1 |
| Key Information | 5 | 1 |
| Key Facts | 6 | 1 |
| XOMA Corporation Research and Development Overview | 7 | 2 |
| Key Therapeutic Areas | 7 | 2 |
| XOMA Corporation Pipeline Review | 9 | 4 |
| Pipeline Products by Stage of Development | 9 | 1 |
| Pipeline Products Monotherapy | 10 | 1 |
| Pipeline Products Out-Licensed Products | 11 | 1 |
| Out-Licensed Products/Combination Treatment Modalities | 12 | 1 |
| XOMA Corporation Pipeline Products Glance | 13 | 4 |
| XOMA Corporation Clinical Stage Pipeline Products | 13 | 1 |
| Phase II Products/Combination Treatment Modalities | 13 | 1 |
| Phase I Products/Combination Treatment Modalities | 14 | 1 |
| XOMA Corporation Early Stage Pipeline Products | 15 | 1 |
| Preclinical Products/Combination Treatment Modalities | 15 | 1 |
| Discovery Products/Combination Treatment Modalities | 16 | 1 |
| XOMA Corporation Drug Profiles | 17 | 10 |
| XOMA-213 | 17 | 1 |
| Product Description | 17 | 1 |
| Mechanism of Action | 17 | 1 |
| R&D Progress | 17 | 2 |
| XOMA-358 | 19 | 1 |
| Product Description | 19 | 1 |
| Mechanism of Action | 19 | 1 |
| R&D Progress | 19 | 1 |
| Monoclonal Antibodies for Undisclosed Disease | 20 | 1 |
| Product Description | 20 | 1 |
| Mechanism of Action | 20 | 1 |
| R&D Progress | 20 | 1 |
| Monoclonal Antibodies to Antagonize Adrenal Corticotropic Hormone Receptor for Cushing s Disease | 21 | 1 |
| Product Description | 21 | 1 |
| Mechanism of Action | 21 | 1 |
| R&D Progress | 21 | 1 |
| Monoclonal Antibodies to Antagonize Parathyroid Hormone 1 Receptor for Hyperparathyroidism and Malignancy Induced Hypercalcemia | 22 | 1 |
| Product Description | 22 | 1 |
| Mechanism of Action | 22 | 1 |
| R&D Progress | 22 | 1 |
| XMet-A | 23 | 1 |
| Product Description | 23 | 1 |
| Mechanism of Action | 23 | 1 |
| R&D Progress | 23 | 1 |
| XOMA-129 | 24 | 1 |
| Product Description | 24 | 1 |
| Mechanism of Action | 24 | 1 |
| R&D Progress | 24 | 1 |
| XOMA-3-BB | 25 | 1 |
| Product Description | 25 | 1 |
| Mechanism of Action | 25 | 1 |
| R&D Progress | 25 | 1 |
| Antibody to Modulate GPCR | 26 | 1 |
| Product Description | 26 | 1 |
| Mechanism of Action | 26 | 1 |
| R&D Progress | 26 | 1 |
| XOMA Corporation Pipeline Analysis | 27 | 4 |
| XOMA Corporation Pipeline Products by Target | 27 | 1 |
| XOMA Corporation Pipeline Products by Route of Administration | 28 | 1 |
| XOMA Corporation Pipeline Products by Molecule Type | 29 | 1 |
| XOMA Corporation Pipeline Products by Mechanism of Action | 30 | 1 |
| XOMA Corporation Recent Pipeline Updates | 31 | 3 |
| XOMA Corporation Dormant Projects | 34 | 1 |
| XOMA Corporation Discontinued Pipeline Products | 35 | 1 |
| Discontinued Pipeline Product Profiles | 35 | 1 |
| gevokizumab | 35 | 1 |
| XOMA Corporation Company Statement | 36 | 3 |
| XOMA Corporation Locations And Subsidiaries | 39 | 1 |
| Head Office | 39 | 1 |
| Other Locations &Subsidiaries | 39 | 1 |
| Appendix | 40 | 2 |
| Methodology | 40 | 1 |
| Coverage | 40 | 1 |
| Secondary Research | 40 | 1 |
| Primary Research | 40 | 1 |
| Expert Panel Validation | 40 | 1 |
| Contact Us | 40 | 1 |
| Disclaimer | 41 | 1 |